Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling

13. november 2026 oppdatert av: Ömer Keklicek, Konya City Hospital

Effect of Preoperative Ultrasound-Guided Bilateral Greater Occipital Nerve Block on Postoperative Headache Following Endovascular Coiling of Unruptured Intracranial Aneurysms: A Prospective, Randomized, Sham-Controlled Trial

Postoperative headache is a common complication following endovascular coil embolization of intracranial aneurysms and may increase analgesic requirements, impair patient comfort, and contribute to hemodynamic instability.

The greater occipital nerve (GON) has anatomical and functional connections with the trigeminocervical complex, suggesting that greater occipital nerve blockade may modulate headache-related pain pathways. However, the effectiveness of prophylactic greater occipital nerve block in patients undergoing elective endovascular coiling of unruptured intracranial aneurysms remains uncertain.

This prospective, randomized, sham-controlled, single-center clinical trial aims to investigate whether preoperative ultrasound-guided bilateral greater occipital nerve block reduces postoperative headache intensity during the first 24 hours following endovascular coil embolization.

A total of 76 patients will be randomly allocated in a 1:1 ratio to receive either ultrasound-guided bilateral greater occipital nerve block with 0.25% bupivacaine or bilateral superficial sham injections with 0.9% normal saline.

The active intervention will consist of 3 mL of 0.25% bupivacaine administered on each side in the fascial plane between the semispinalis capitis and obliquus capitis inferior muscles. The control intervention will consist of a superficial subcutaneous injection of 0.5 mL of 0.9% normal saline on each side.

All participants will receive standardized general anesthesia and postoperative multimodal analgesia.

The primary outcome will be the time-weighted average resting pain score during the first 24 postoperative hours, calculated from the area under the Numeric Rating Scale (NRS) pain score-time curve.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

76

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Ömer Keklicek, Principal Investigator
  • Telefonnummer: +905399291702
  • E-post: drokeklicek@gmail.com

Studiesteder

    • Konya
      • Konya, Konya, Tyrkia (Türkiye), 42090
        • Rekruttering
        • Konya City Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients aged 18-65 years.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Patients scheduled for elective endovascular coil embolization of a unilateral unruptured intracranial aneurysm under general anesthesia.
  • Ability and willingness to provide written informed consent.

Exclusion Criteria:

  • Refusal to provide informed consent or subsequent withdrawal of consent.
  • Ruptured intracranial aneurysm or acute subarachnoid hemorrhage requiring emergency intervention.
  • Clinical contraindications to greater occipital nerve block, including infection or skin lesions at the injection site, local anesthetic allergy, or anatomical conditions preventing safe needle placement.
  • Platelet count below 100,000/mm³, international normalized ratio (INR) greater than 1.5, activated partial thromboplastin time (aPTT) greater than 1.5 times normal, or clinically significant coagulopathy.
  • Antithrombotic or antiplatelet treatment that does not meet the predefined safety intervals for deep peripheral nerve blocks according to the ASRA 2025 and ESAIC/ESRA guidelines.
  • Moderate-to-severe preoperative headache, defined as a resting Numeric Rating Scale score of 3 or higher.
  • Known history of severe hypersensitivity or allergic reactions to local anesthetics.
  • Chronic opioid use, chronic pain syndrome, or regular analgesic use that may substantially interfere with postoperative pain assessment.
  • Uncontrolled hypertension or clinically significant uncontrolled cardiac arrhythmia.
  • Pregnancy or breastfeeding.
  • Neurological deficits, aphasia, impaired consciousness, cognitive impairment, or communication difficulties preventing reliable pain assessment using the Numeric Rating Scale.
  • Body mass index greater than 35 kg/m².
  • Clinical circumstances requiring initiation of intravenous unfractionated heparin within one hour after the planned study-related needle intervention.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Postoperative headache is a common complication following endovascular coil embolization of intracra

Participants assigned to the experimental group will receive preoperative ultrasound-guided bilateral greater occipital nerve block with 0.25% bupivacaine before induction of general anesthesia.

A total of 3 mL of 0.25% bupivacaine (7.5 mg) will be administered on each side into the interfascial plane between the semispinalis capitis and obliquus capitis inferior muscles. The total bilateral dose will be 15 mg of bupivacaine in 6 mL.

The intervention will be performed while the patient is awake and able to communicate, without routine deep sedation.

All participants will subsequently receive standardized general anesthesia and postoperative multimodal analgesia.

Ultrasound-guided bilateral greater occipital nerve block will be performed before general anesthesia induction using a high-frequency linear ultrasound transducer.

The greater occipital nerve will be identified between the semispinalis capitis and obliquus capitis inferior muscles. A 25-gauge, 50-mm echogenic needle will be advanced under continuous ultrasound guidance using an in-plane approach.

Following color Doppler assessment and negative aspiration, 3 mL of 0.25% bupivacaine (7.5 mg) will be injected slowly and incrementally on each side.

The total bilateral dose will be 15 mg of bupivacaine.

Sham-komparator: Bilateral Superficial Sham Injection

Participants assigned to the control group will receive bilateral superficial subcutaneous sham injections with 0.9% normal saline before induction of general anesthesia.

Following the same general preparation, positioning, and ultrasound examination as the experimental group, 0.5 mL of 0.9% normal saline will be injected subcutaneously on each side of the occipital region using a short 27-gauge needle.

The total bilateral injection volume will be 1 mL.

The needle will not be advanced into the deep interfascial plane, and no injection will be performed around the greater occipital nerve.

All participants will receive standardized general anesthesia and postoperative multimodal analgesia.

A bilateral superficial subcutaneous sham injection will be performed before general anesthesia induction.

Following standardized positioning, skin antisepsis, and ultrasound examination, a short 27-gauge needle will be used to administer 0.5 mL of 0.9% normal saline subcutaneously on each side of the occipital region.

The total bilateral injection volume will be 1 mL.

The needle will not be advanced into the deep interfascial plane, and the greater occipital nerve will not be directly targeted.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time-Weighted Average Resting Pain Score During the First 24 Postoperative Hours
Tidsramme: From postoperative hour 0 to postoperative hour 24

Postoperative resting pain intensity will be assessed using the 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain).

NRS scores will be recorded at postoperative hours 0, 2, 4, 6, 8, 12, and 24.

The area under the NRS pain score-time curve (AUC0-24) will be calculated using the linear trapezoidal method and divided by 24 hours to obtain the time-weighted average NRS score.

The resulting patient-level value will range from 0 to 10, with higher scores indicating greater overall postoperative pain intensity.

From postoperative hour 0 to postoperative hour 24

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. november 2026

Primær fullføring (Antatt)

2. november 2027

Studiet fullført (Antatt)

2. desember 2027

Datoer for studieregistrering

Først innsendt

27. oktober 2026

Først innsendt som oppfylte QC-kriteriene

27. oktober 2026

Først lagt ut (Faktiske)

2. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2026_KAEK-64_28

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .